Pazital, the fixed-dose combination of Acetaminophen and Tramadol, is used in situations involving certain distressing symptoms. It is applied across therapeutic domains where additional symptomatic support is needed, typically when non-opioid medications are considered insufficient.

The combination is generally indicated for the management of acute pain that is severe enough to require an opioid analgesic. This medication is relevant for managing symptoms related to physical discomfort that interfere with daily functioning, covering symptom clusters of moderate to severe intensity.

The primary uses include its application in settings where short-term symptomatic assistance is needed for acute painful episodes, relief of postoperative discomfort following surgical procedures, and management of pain in select chronic conditions such as musculoskeletal pain or painful diabetic peripheral neuropathy.

Quick Fact: Relief for Moderate to Severe Pain

This fixed-dose medicine contributes to easing the overall symptom load by providing a multimodal analgesic action. It is commonly used when symptoms become temporarily overwhelming.

“The formulation is considered relevant in contexts involving heightened systemic burden, supports the patient during difficult episodes by easing distress.”

It may assist with managing symptoms that create noticeable physiological strain, helping maintain a sense of stability when symptoms are more noticeable.

The eligibility for using Pazital, a fixed-dose combination of Acetaminophen and Tramadol, is strictly defined by regulatory guidelines, primarily due to the opioid component. The medicine is authorized for use in adults (18 years and older).

Populations for Whom Use Is Contraindicated

Use is contraindicated (absolutely prohibited) in several patient groups, including:

• Children younger than 12 years of age.
• Adolescents younger than 18 years following tonsillectomy or adenoidectomy.
• Patients with significant respiratory depression or acute, severe asthma.
• Patients with a history of hypersensitivity to tramadol, acetaminophen, or any component of the product.
• Patients using Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of use.
• Patients with known or suspected gastrointestinal obstruction (e.g., paralytic ileus).

Conditions and Physiological Restrictions

Use is not recommended or restricted in other specific populations:

• Organ Function: Use is generally not recommended for patients with severe hepatic impairment or severe renal impairment due to the risk of drug or metabolite accumulation.
• Pregnancy and Lactation: Use is contraindicated for breastfeeding mothers and not recommended during the third trimester of pregnancy.
• Seizure Risk: Use requires caution in patients with a history of seizures.

This section summarizes the official information regarding Pazital's (tramadol/paracetamol) documented interactions with other medicines and products, as specified in regulatory labeling.

Major Interaction Restrictions

The coadministration of Pazital with certain medication classes is either contraindicated or requires strict caution due to the risk of serious adverse effects. The most severe restrictions involve:

• Monoamine Oxidase Inhibitors (MAOIs): Concurrent use is strictly contraindicated, as is use within 14 days of stopping an MAOI (e.g., phenelzine, linezolid). This is due to an increased risk of Serotonin Syndrome and seizures.
• Central Nervous System (CNS) Depressants: Combining with other CNS depressants, including benzodiazepines, other opioids, sedatives, hypnotics, and alcohol, should be avoided or reserved for cases where alternative options are inadequate. This combination significantly increases the risk of respiratory depression, profound sedation, coma, and death.

Other Documented Interactions

Interactions also arise from the effects of other substances on the drug's metabolism and function:

Interacting Product Category	Official Constraint/Implication
Serotonergic Drugs (e.g., SSRIs, triptans)	Increased risk of Serotonin Syndrome; use with caution.
CYP3A4/CYP2D6 Inhibitors (e.g., ketoconazole, quinidine)	May increase tramadol exposure and decrease the active metabolite, requiring monitoring.
CYP3A4 Inducers (e.g., carbamazepine, rifampin)	May reduce tramadol exposure, potentially decreasing the effectiveness of the product.
Warfarin and Coumarins	Requires periodic assessment of prothrombin time due to the potential for altered anticoagulant effect.
Other Paracetamol-Containing Products	Use must be avoided to prevent exceeding the maximum recommended daily dose and to mitigate the risk of severe liver injury.

How Pazital Works

Pazital functions through a dual pharmacodynamic mechanism, targeting both opioid receptors and specific monoamine transporters within the central nervous system. The parent compound, along with its active O-desmethyl-metabolite (M1), acts as an agonist at the mu-opioid receptor, which is a G-protein coupled receptor. Activation of this receptor modulates neurotransmitter release and neuronal excitability across various nociceptive pathways, primarily within the spinal cord and periaqueductal gray matter.

Simultaneously, Pazital exerts a secondary action by inhibiting the reuptake of both norepinephrine and serotonin at the sodium-dependent membrane transporters. By reducing the clearance of these monoamines from the synaptic cleft, Pazital increases the concentration and duration of neurotransmitter activity. This process potentiates the descending inhibitory pathways originating from the brainstem, contributing to the modulation of afferent sensory signaling. The combined receptor agonism and monoamine reuptake inhibition define the compound's multifaceted intracellular cascade and system-level physiological effect on signal transmission.

How to use Pazital

Pazital is administered exclusively via the oral route as a fixed-dose combination tablet containing Tramadol Hydrochloride 37.5 mg and Acetaminophen 325 mg. This formulation approach is designed to ensure controlled delivery of both components.

Standard Dosing Schedule

The typical initial dose for adults and adolescents 12 years and older is two tablets (equivalent to 75 mg Tramadol / 650 mg Acetaminophen). Subsequent doses are spaced according to a specified interval, which must be not less than four to six hours. The maximum amount of Pazital that may be taken in a 24-hour period is limited to eight tablets (300 mg Tramadol / 2600 mg Acetaminophen).

Administration may occur with or without food. Proper administration requires that the tablet be swallowed whole with liquid and must not be chewed or crushed to maintain the integrity of the formulation. The duration of use for acute painful episodes is defined as short-term, typically restricted to five days or less. If a dose is missed, instructions specify skipping that dose and continuing with the regular schedule, rather than taking a double dose.

Population-Specific Use Adjustments

Modifications are utilized for specific patient groups. For individuals with impaired renal function (creatinine clearance less than 30 mL/min), the maximum dosage is reduced to two tablets every 12 hours. Use is not recommended in patients with severe hepatic impairment or in pediatric patients younger than 12 years of age. For older adults (over 75 years), the minimum dosing interval should be extended to at least six hours.

Research evidence / Overview of studies for Pazital

This overview describes the research landscape for the fixed-dose combination of acetaminophen and tramadol, focusing on the types of clinical studies that have been conducted and the questions they were designed to answer.

Evidence for Acute Pain Management

The core research for the combination, particularly in the context of moderate to severe pain, is based on high-quality, short-term Randomized Controlled Trials (RCTs) and comprehensive Meta-analyses. These studies typically include adult patients managing temporary, high-intensity pain. Research was conducted during periods of increased symptom activity, and studies monitored outcomes related to physical discomfort.

The trials explored short-term symptom changes, focusing on how quickly a reported pain change was observed and how long that measured change appeared to last. Findings described patterns observed in the studies related to pain score measurements over this short-term period. Research has been conducted for acute pain, but long-term outcomes are not well characterized. The available research provides limited insight into outcomes from repeated or extended use for acute pain episodes.

Evidence for Chronic Pain Conditions

Research was studied for the combination's role in managing longer-term pain, including conditions characterized by functional limitations, such as chronic low back pain and pain associated with osteoarthritis. The studies in this area were typically RCTs with an intermediate follow-up duration, often ranging from four to twelve weeks.

Studies observed responses over defined time intervals, and research highlights measurements of pain and function that were recorded during the study period when compared to a placebo. Some studies observed that the magnitude of reported changes in pain scores and functional outcomes varied across the trial period. Studies in this research domain have been limited by their follow-up duration, and there is limited information for long-term outcomes.

Studies in Specific Patient Populations

Specific patient groups have been evaluated, including adults with Painful Diabetic Peripheral Neuropathy (PDPN) through dedicated RCTs. These studies monitored patient-reported outcomes describing perceived discomfort over an intermediate timeframe (e.g., 6 to 12 weeks), and research describes how symptoms evolved in the observed populations. Observational studies have also been applied in examining patient-reported experiences in Older Adults.

Common questions about Pazital (FAQ)

Q: How quickly does Pazital start to work after taking it?

According to official pharmacokinetic data, the pain-relieving effects of the immediate-release combination generally begin within 30 to 60 minutes after a dose is taken. This marks the typical time when patients may begin to observe a change in their symptoms.

---

Q: How long does the effect of one dose of Pazital last?

The official product information indicates that the pain relief from the immediate-release formulation of Pazital typically lasts for approximately four to six hours. This duration is consistent with the minimum interval specified between doses outlined in the regulatory guidelines for proper use.

---

Q: Is it normal to feel [a common, non-severe side effect] when starting Pazital?

Adverse events such as nausea, dizziness, and somnolence are classified in official documents as Very Common or Common. Because these effects were frequently reported in clinical trials, they are considered expected occurrences, particularly when a patient first begins their treatment regimen.

---

Q: How long before or after taking Pazital can I have alcohol?

The coadministration of alcohol with Pazital is strongly discouraged by official warnings. This is due to a significantly increased risk of severe effects, including profound sedation and potentially life-threatening respiratory depression. Official sources do not specify a safe timeframe for consuming alcohol before or after taking a dose.

---

Q: What are the official guidelines for stopping Pazital?

Official prescribing information warns that stopping the medicine abruptly, particularly after prolonged use, can lead to withdrawal symptoms such as restlessness and anxiety. The regulatory label describes discontinuation as a process that involves a gradual dose reduction, which is intended to minimize these effects.

---

Q: Does Pazital require a special prescription?

Yes, Pazital contains tramadol, which is classified as a Schedule IV controlled substance by regulatory bodies like the DEA. This classification means that the medicine requires a specific prescription from a licensed healthcare provider for its use.

---

Q: Do the side effects of Pazital go away over time?

The prescribing information does not explicitly guarantee that side effects will resolve. However, documented experience suggests that the most commonly experienced effects may lessen in frequency or severity over the first few days of use. Conversely, the official label notes that the risk of serious issues like dependence increases with prolonged use.

---

Q: Can Pazital affect my ability to drive or operate machinery?

Official warnings state that this medicine may cause effects like drowsiness, dizziness, and reduced concentration or coordination. For this reason, regulatory documents contain warnings against driving, operating machinery, or engaging in hazardous activities until an individual is aware of how the medicine affects them.

---

Q: Do I need any special tests while taking Pazital?

While general monitoring is not a universal requirement for all patients, official information describes potential risks that may require monitoring, such as liver toxicity due to the acetaminophen component. Additionally, patients taking blood thinners like warfarin require periodic assessment of their prothrombin time due to a known drug interaction risk.

---

Q: Does Pazital affect blood pressure?

Yes, official documents state that the medicine may cause low blood pressure, or hypotension, which has the potential to be severe. Due to this risk, medical monitoring of blood pressure is a factor considered, especially when treatment is first initiated.

---

Q: Can Pazital cause skin sensitivity to the sun?

Official regulatory documents do not list photosensitivity or increased skin sensitivity to the sun as a reported common side effect. However, it is noted that rare but serious skin reactions, such as Stevens-Johnson Syndrome, have been documented in the prescribing information.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store at Controlled Room Temperature (20^circmathrmC to 25^circmathrmC).
Environmental Protection	Protect from excessive heat, moisture, and direct light. Do not freeze the product.
Container	Keep the medicine in a tightly closed container.

Child Safety and Disposal

As a Schedule IV controlled substance, Pazital must be stored securely and kept strictly out of the sight and reach of children and pets to prevent accidental ingestion, which can be fatal.

Disposal procedures are specific to controlled substances: the preferred method is to drop off unused or expired tablets at an authorized drug take-back location. If this is unavailable, the tablets must be mixed with an undesirable substance (like coffee grounds or dirt) in a sealed bag and discarded in the household trash, following official guidance to prevent misuse.